{
    "clinical_study": {
        "@rank": "98989", 
        "arm_group": [
            {
                "arm_group_label": "sipuleucel-T", 
                "arm_group_type": "Active Comparator", 
                "description": "Sipuleucel-T will be administered intravenously per standard of care biweekly, weeks 0, 2, and 4."
            }, 
            {
                "arm_group_label": "sipuleucel-T with DNA Vaccine", 
                "arm_group_type": "Experimental", 
                "description": "Sipuleucel-T will be administered intravenously per standard of care biweekly, weeks 0, 2, and 4.\nThen, DNA vaccine (pTVG-HP (100 \u00b5g) with rhGM-CSF (208 \u00b5g)) will be administered intradermally biweekly (weeks 6, 8, 10, 12), then every 3 months (months 6 and 9) to complete a 1-year treatment period."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to try to enhance subjects' own immune response against\n      prostate cancer.  In this study the investigators will be testing the effectiveness of\n      adding pTVG-HP vaccine with Sipuleucel-T (Provenge)."
        }, 
        "brief_title": "Provenge With or Without pTVG-HP DNA Booster Vaccine in Prostate Cancer", 
        "completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Prostate Cancer", 
        "condition_browse": {
            "mesh_term": "Prostatic Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Diagnosis of Prostate Cancer\n\n          -  Castrate Resistant Disease\n\n          -  Progressive disease despite androgen deprivation therapy as defined by rising PSA\n             levels or progressive soft tissue or bony disease\n\n          -  Normal organ function per laboratory tests\n\n          -  Life expectancy of at least 6 months\n\n        Exclusion Criteria:\n\n          -  History of life-threatening autoimmune disease\n\n          -  Small cell or other variant prostate cancer histology\n\n          -  Serum testosterone at screening < 50 ng/dL\n\n          -  Prior cytotoxic chemotherapy within 6 months of registration\n\n          -  Patients who have undergone splenectomy\n\n          -  Radiation therapy within 4 weeks of registration is prohibited, or anticipated need\n             for radiation therapy (e.g. imminent pathological fracture or spinal cord\n             compression) within 3 months of registration.\n\n          -  Another malignancy other than non-melanoma skin cancer or carcinoma in situ of the\n             bladder.  Subjects with a history of other curatively treated cancers are eligible.\n\n          -  Known brain metastases\n\n          -  Any antibiotic therapy or evidence of infection within 1 week of registration"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 9, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01706458", 
            "org_study_id": "CO11816"
        }, 
        "intervention": [
            {
                "arm_group_label": "sipuleucel-T", 
                "intervention_name": "sipuleucel-T", 
                "intervention_type": "Biological", 
                "other_name": "Provenge"
            }, 
            {
                "arm_group_label": "sipuleucel-T with DNA Vaccine", 
                "intervention_name": "DNA Vaccine", 
                "intervention_type": "Biological", 
                "other_name": "pTVG-HP with rhGM-CSF"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Vaccine", 
            "pTVG-HP", 
            "Prostate Cancer", 
            "Castrate Resistant"
        ], 
        "lastchanged_date": "May 10, 2013", 
        "link": {
            "description": "University of Wisconsin Carbone Cancer Center", 
            "url": "http://www.uwhealth.org/uw-carbone-cancer-center/cancer/10252"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Madison", 
                    "country": "United States", 
                    "state": "Wisconsin", 
                    "zip": "53792"
                }, 
                "name": "University of Wisconsin Carbone Cancer Center"
            }, 
            "investigator": {
                "last_name": "Douglas McNeel, M.D., PhD.", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Pilot Trial of Sipuleucel-T, With or Without pTVG-HP DNA Booster Vaccine, in Patients With Castrate-Resistant, Metastatic Prostate Cancer", 
        "other_outcome": [
            {
                "measure": "Overall Survival", 
                "safety_issue": "No", 
                "time_frame": "5 years"
            }, 
            {
                "measure": "Number of Circulating Tumor Cells", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "measure": "PAP-specific antibody and T-cell immune responses following treatment with sipuleucel-T and DNA vaccine will be summarized in tabular format.", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "measure": "Logistic regression analysis will be conducted to evaluate whether PAP-specific immune response is associated with prolonged (1-year) progression-free survival.", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "measure": "Logistic regression analysis will be conducted to evaluate whether baseline immune responses predict for immune responses elicited/augmented following treatment with sipuleucel-T +/- DNA vaccine.", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "measure": "The detection of antigen spread to other prostate associated antigens, and the identification of specific antigens recognized, will be analyzed descriptively.", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }
        ], 
        "overall_contact": {
            "email": "cancerconnect@uwcarbone.wisc.edu", 
            "last_name": "Cancer Connect", 
            "phone": "800-622-8922"
        }, 
        "overall_official": [
            {
                "affiliation": "University of Wisconsin, Madison", 
                "last_name": "Douglas McNeel, M.D., PhD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "University of Wisconsin, Madison", 
                "last_name": "Glenn Liu, MD", 
                "role": "Study Chair"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United States: Data and Safety Monitoring Board"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Measure immune responses following treatment with sipuleucel-T", 
            "safety_issue": "No", 
            "time_frame": "12 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01706458"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of Wisconsin, Madison", 
            "investigator_full_name": "Douglas McNeel", 
            "investigator_title": "Principle Investigator", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "Progression-free Survival", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "measure": "Time to radiographic disease progression", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "measure": "Measure prostate-specific antigen (PSA) doubling time", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }
        ], 
        "source": "University of Wisconsin, Madison", 
        "sponsors": {
            "collaborator": {
                "agency": "Dendreon", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "University of Wisconsin, Madison", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2013"
    }
}